Haleon invests over £43mn to upgrade its Richmond R&D facility

Haleon is enhancing its research and development (R&D) capabilities and accelerating its new product innovation pipeline with a $54 million (£43.49 million) investment in its global R&D centre of excellence in Richmond,
Virginia, USA.

This investment is in addition to the company’s annual R&D budget of approximately £300 million.

The Richmond site, one of Haleon’s three global R&D centres of excellence, alongside facilities in Weybridge, UK, and Suzhou, China, provides the global scale necessary for the company to deliver disruptive and locally relevant
brand innovations across over 170 markets worldwide.

The upgraded facility will feature new, state-of-the-art laboratories designed to enable development of innovations across ingredients, formulations, flavours, formats and packaging for Haleon’s Over-the-Counter (OTC) and Vitamins,
Minerals and Supplements (VMS) categories.

Franck Riot, Haleon’s chief R&D officer, emphasised the critical role of R&D in the company’s success, stating, “R&D is the cornerstone of our business and the innovation engine behind our category-leading brands.”

“Consumers trust our products because they trust our science – so investing in R&D is vital for driving consumer preference for our brands.”